Insider Transactions in Q1 2021 at Exelixis, Inc. (EXEL)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 29
2021
|
Jack L Wyszomierski Director |
SELL
Open market or private sale
|
Direct |
6,220
-2.62%
|
$136,840
$22.64 P/Share
|
|
Mar 29
2021
|
Jack L Wyszomierski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+14.4%
|
$120,000
$3.38 P/Share
|
|
Mar 15
2021
|
Alan M Garber Director |
SELL
Open market or private sale
|
Direct |
40,000
-75.88%
|
$920,000
$23.6 P/Share
|
|
Mar 15
2021
|
Alan M Garber Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+43.14%
|
$120,000
$3.38 P/Share
|
|
Mar 04
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
49,395
+11.26%
|
-
|
|
Mar 04
2021
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
59,570
+16.34%
|
-
|
|
Mar 04
2021
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
64,150
+15.25%
|
-
|
|
Mar 04
2021
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
57,135
+8.12%
|
-
|
|
Mar 04
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
72,885
+10.62%
|
-
|
|
Mar 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
65,000
-16.05%
|
$1,430,000
$22.11 P/Share
|
|
Mar 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+13.83%
|
$65,000
$1.7 P/Share
|
|
Feb 24
2021
|
Michael Morrissey President and CEO |
BUY
Bona fide gift
|
Indirect |
67,374
+5.98%
|
-
|
|
Feb 24
2021
|
Michael Morrissey President and CEO |
SELL
Bona fide gift
|
Direct |
67,374
-12.05%
|
-
|
|
Feb 24
2021
|
Charles Cohen Director |
SELL
Open market or private sale
|
Direct |
40,000
-18.07%
|
$880,000
$22.69 P/Share
|
|
Feb 24
2021
|
Charles Cohen Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+15.3%
|
$120,000
$3.38 P/Share
|
|
Feb 23
2021
|
Lance Willsey Director |
SELL
Open market or private sale
|
Direct |
40,000
-4.31%
|
$880,000
$22.13 P/Share
|
|
Feb 23
2021
|
Lance Willsey Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+7.93%
|
$120,000
$3.38 P/Share
|
|
Feb 22
2021
|
Vincent T Marchesi Director |
SELL
Open market or private sale
|
Direct |
24,097
-26.71%
|
$530,134
$22.29 P/Share
|
|
Feb 22
2021
|
George Poste Director |
BUY
Exercise of conversion of derivative security
|
Direct |
40,000
+16.81%
|
$120,000
$3.38 P/Share
|
|
Feb 18
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
50,000
-8.47%
|
$1,100,000
$22.35 P/Share
|
|
Feb 18
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.81%
|
$50,000
$1.7 P/Share
|
|
Feb 17
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Open market or private sale
|
Direct |
50,000
-8.47%
|
$1,100,000
$22.5 P/Share
|
|
Feb 17
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+7.81%
|
$50,000
$1.7 P/Share
|
|
Feb 16
2021
|
Lance Willsey Director |
SELL
Open market or private sale
|
Direct |
50,000
-10.54%
|
$1,050,000
$21.9 P/Share
|
|
Feb 16
2021
|
Carl B Feldbaum Director |
SELL
Open market or private sale
|
Direct |
20,000
-70.12%
|
$420,000
$21.96 P/Share
|
|
Feb 16
2021
|
Carl B Feldbaum Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+41.22%
|
$60,000
$3.38 P/Share
|
|
Feb 15
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,718
-1.08%
|
$78,078
$21.91 P/Share
|
|
Feb 15
2021
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,789
-1.72%
|
$205,569
$21.91 P/Share
|
|
Feb 15
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,858
-0.53%
|
$60,018
$21.91 P/Share
|
|
Feb 15
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,685
-0.29%
|
$35,385
$21.91 P/Share
|
|
Feb 15
2021
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
4,105
-1.38%
|
$86,205
$21.91 P/Share
|
|
Feb 15
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
1,400
-0.57%
|
$29,400
$21.91 P/Share
|
|
Feb 12
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Open market or private sale
|
Direct |
45,000
-15.42%
|
$945,000
$21.57 P/Share
|
|
Feb 03
2021
|
Christopher J. Senner EVP and CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
18,206
-5.78%
|
$400,532
$22.56 P/Share
|
|
Feb 03
2021
|
Christopher J. Senner EVP and CFO |
BUY
Grant, award, or other acquisition
|
Direct |
69,156
+9.78%
|
-
|
|
Feb 03
2021
|
Patrick J. Haley EVP, Commercial |
SELL
Payment of exercise price or tax liability
|
Direct |
11,267
-3.72%
|
$247,874
$22.56 P/Share
|
|
Feb 03
2021
|
Patrick J. Haley EVP, Commercial |
BUY
Grant, award, or other acquisition
|
Direct |
63,909
+9.1%
|
-
|
|
Feb 03
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
14,982
-2.68%
|
$329,604
$22.56 P/Share
|
|
Feb 03
2021
|
Gisela Schwab Pres, Prod Dev & Med Aff & CMO |
BUY
Grant, award, or other acquisition
|
Direct |
81,038
+6.64%
|
-
|
|
Feb 03
2021
|
Jeffrey Hessekiel EVP & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
15,365
-2.53%
|
$338,030
$22.56 P/Share
|
|
Feb 03
2021
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
64,409
+4.92%
|
-
|
|
Feb 03
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
19,997
-5.5%
|
$439,934
$22.56 P/Share
|
|
Feb 03
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Grant, award, or other acquisition
|
Direct |
80,663
+9.75%
|
-
|
|
Feb 03
2021
|
Michael Morrissey President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
65,190
-10.28%
|
$1,434,180
$22.56 P/Share
|
|
Feb 03
2021
|
Michael Morrissey President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
23,238
+5.37%
|
-
|
|
Feb 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
SELL
Open market or private sale
|
Direct |
65,000
-18.67%
|
$1,430,000
$22.08 P/Share
|
|
Feb 01
2021
|
Peter Lamb EVP, Scientific Strategy & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
65,000
+15.73%
|
$65,000
$1.7 P/Share
|
|
Jan 12
2021
|
Christopher J. Senner EVP and CFO |
SELL
Open market or private sale
|
Direct |
30,000
-10.89%
|
$750,000
$25.0 P/Share
|
|
Jan 12
2021
|
Christopher J. Senner EVP and CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+9.82%
|
$90,000
$3.66 P/Share
|
|
Jan 04
2021
|
Jeffrey Hessekiel EVP & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+4.5%
|
$200,000
$4.59 P/Share
|